On Thursday, Genpact earned a positive adjustment to its Relative Strength (RS) Rating, from 66 to 72.
This unique rating measures technical performance by showing how a stock's price action over the last 52 weeks measures up against that of the other stocks in our database.
History shows that the top-performing stocks often have an RS Rating north of 80 in the early stages of their moves. See if Genpact can continue to show renewed price strength and hit that benchmark.
Can You Really Time The Stock Market?
Genpact is trying to complete a flat base with a 39.95 buy point. See if the stock can clear the breakout price in heavy trade.
Top and bottom line growth moved higher last quarter. Earnings were up 10%, compared to 7% in the prior report. Revenue increased from 4% to 6%. Look for the next report on or around Nov. 7.
The company earns the No. 8 rank among its peers in the Commercial Services-Outsourcing industry group. ExlService Holdings, Red Violet and HealthEquity are among the top 5 highly rated stocks within the group.
RELATED:
Which Stocks Are Showing Improved Price Performance?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
